PRESS RELEASE — Jan 6 — Galderma Laboratories, L.P. today announced the availability of Epiduo™ (adapalene and benzoyl peroxide) Gel 0.1% / 2.5%, the first and only, once-daily, topical acne treatment that combines the well-tolerated retinoid adapalene, and benzoyl peroxide, a well-known antimicrobial with no evidence of promoting bacterial resistance.1 The new prescription acne treatment received approval from the U.S. Food and Drug Administration in December, and will be on pharmacy shelves nationwide in the first quarter of 2009. READ FULL PRESS RELEASE @ GALDERMA LABORATORIES


CAAH Summary: Galderma, the company behind the well-known brands Cetaphil and Differin, is launching a new acne treatment called Epiduo. Similar to Differin, Epiduo is a retinoid prescriptive product. It differs from Differin gel in that it will also contain benzoyl peroxide. The product will be available for sale sometime during the first quarter of 2009 and has been approved to be used by patients 12 years old and older.

Image credit: Walter Watzpatzkowski

Related posts:

1. A Look At Benzoyl Peroxide For Acne
2. Studies Show Combination Laser Therapy Effective at Clearing Acne, Reducing Oil Production
3. Laser Acne Treatment
4. Acne Treatment Information: Accutane Side Effects & Patient Information
5. The Voluntary Recall of Accutane

Fatal error: Call to undefined function adsensem_ad() in /home/cur10000/public_html/wp-content/themes/arthemia/single.php on line 26